grant
Synthetic multi-component influenza vaccines to elicit broad immunity
Organization UNIVERSITY OF GEORGIALocation ATHENS, UNITED STATESPosted 19 Dec 2023Deadline 31 Oct 2028
NIHUS FederalResearch GrantFY2025AddressAdjuvantAgonistAnimal ModelAnimal Models and Related StudiesAntibodiesAntigenic DeterminantsAntigensAreaAssayB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBinding DeterminantsBioassayBiological AssayCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCancer ModelCancerModelCell Surface AntigensCessation of lifeChemicalsChemistryDeathDiseaseDisorderElderlyEpitopesFerretsFlu vaccinationGlycansGlycoconjugatesGlycoengineeringGlycopeptidesGlycoproteinsGoalsGrippeHealthHemagglutininHumanImmuneImmune responseImmunesImmunityImmunoactivatorsImmunoadjuvantsImmunochemical ImmunologicImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunologicImmunologic AdjuvantsImmunologicalImmunological Surface MarkersImmunologicallyImmunologicsImmunopotentiatorsImmunostimulantsImmunosuppressed HostIndividualInfantInfectionInfluenzaInfluenza AInfluenza A virusInfluenza VaccinesInfluenza VirusInfluenza Viruses Type AInfluenza immunizationInfluenza preventionInfluenza vaccinationInfluenzavirus AIntegral Membrane ProteinIntrinsic Membrane ProteinLicensingLinkLipid AMeasuresMediatingMethodologyMethodsMiceMice MammalsModelingModern ManMurineMusNIAIDNational Institute of Allergy and Infectious DiseaseObesityOrthomyxovirus Type APeptidesPolysaccharidesPopulationPre-Clinical ModelPreclinical ModelsProphylactic vaccination against influenzaProteinsRecombinantsResearchRiskSeasonsSerologySerology testStrategic PlanningSurface AntigensSynthetic VaccinesT cell responseT-Cell EpitopesT-CellsT-LymphocyteT-Lymphocyte EpitopesT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTIL4TLR2TLR2 geneTLR2 receptorTestingToll-Like Receptor 2Toll/Interleukin 1 Receptor-Like 4Toll/Interleukin 1 Receptor-Like 4 GeneToll/Interleukin 1 Receptor-Like Protein 4Transmembrane ProteinTransmembrane Protein GeneType A InfluenzaUpdateVaccinationVaccine AdjuvantVaccine DesignVaccinesViral DiseasesVirusVirus DiseasesZoonosesZoonoticZoonotic Infectionaccess to vaccinationaccess to vaccinesadiposityadvanced ageburden of diseaseburden of illnesschemical synthesiscorpulencecost effective measurescross immunitycross protectioncross reactivitydesigndesigningdevelop a vaccinedevelop vaccinesdevelopment of a vaccinedisease burdenexpectationflu immunisationflu infectionflu preventionflu vaccineflu virus infectionflu virus vaccinegeriatrichost responsehuman modelimmune system responseimmunization strategyimmunogenimmunogenicimmunogenicityimmunoresponseimmunosuppressed patientinfected with fluinfected with flu virusinfected with influenzainfected with influenza virusinfluenza infectioninfluenza virus infectioninfluenza virus vaccinationinfluenza virus vaccineinfluenzavirusinnovateinnovationinnovativeinterestmodel of animalmodel of humannew technologynew vaccinesnext generationnext generation vaccinesnovelnovel technologiesnovel vaccinespan influenza vaccinepan influenza viral vaccinepan influenza virus vaccinepandemicpandemic concernpandemic diseasepandemic potentialpandemic riskpandemic threatpre-clinical studypreclinical studyprevent influenzaresponseseasonal fluseasonal influenzasenior citizenserology assayskillssuccessthymus derived lymphocytetumoruniversal flu vaccineuniversal influenza vaccineuniversal influenza virus vaccineuniversal vaccine against fluuniversal vaccine against influenzavaccination accessvaccination against influenzavaccination availabilityvaccination strategyvaccine accessvaccine against fluvaccine against influenzavaccine availabilityvaccine candidatevaccine developmentvaccine efficacyviral infectionvirus infectionvirus-induced disease
Description preview
PROJECT SUMMARY
Seasonal influenza viruses cause significant disease burden. While seasonal influenza vaccines are available,
these are often poorly efficacious due to mismatch with circulating virus strains, particularly in the populations at
greatest risk of complications from infection, including the elderly, infant, and immunocompromised.…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click